LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09887 LEADS BIOLABS-B

Trading 12-23 13:03:27

48.500

-1.000

-2.02%

High49.540	Low48.200	Vol151.80K
Open49.540	D1 Closing49.500	Amplitude2.71%
Mkt Cap9.65B	Tradable Cap7.42B	Total Shares199.00M
T/O7.39M	T/O Rate0.10%	Tradable Shares153.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":48.5,"timestamp":1766466143341,"preClose":49.5,"halted":0,"volume":151800,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"Trading","change":-1,"latestTime":"12-23 13:03:27","open":49.54,"high":49.54,"low":48.2,"amount":7390442,"amplitude":0.027071,"askPrice":48.5,"askSize":6600,"bidPrice":48.34,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766477400000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":49.5,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0.725221,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/wiki","defaultTab":"wiki","newsList":[{"id":"1198778853","title":"LEADS BIOLABS-B (09887): First Patient Dosed in Phase I Trial for LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=1198778853","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198778853?lang=en_us&edition=fundamental","pubTime":"2025-12-23 12:30","pubTimestamp":1766464216,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase I clinical study evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2593652764","title":"Nanjing Leads Biolabs Doses First Subject in Phase I Trial of LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=2593652764","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593652764?lang=en_us&edition=fundamental","pubTime":"2025-12-23 12:24","pubTimestamp":1766463883,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL5pQPcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2592992579","title":"Nanjing Leads Biolabs Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992579?lang=en_us&edition=fundamental","pubTime":"2025-12-17 18:50","pubTimestamp":1765968650,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. held an extraordinary general meeting on December 17, 2025. At the meeting, shareholders approved the adoption of the H Share Award Scheme as well as another proposal set out in the meeting notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLKQH4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1161","09887"],"gpt_icon":0},{"id":"1119073977","title":"LEADS BIOLABS-B (09887) Proposes H Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1119073977","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119073977?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:48","pubTimestamp":1765802898,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced on December 15, 2025, that the company has submitted filing materials to the China Securities Regulatory Commission (CSRC) for the proposed implementation of H share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"1189833363","title":"HK Stock Investment Diary | December 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1189833363","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189833363?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:03","pubTimestamp":1765469037,"startTime":"0","endTime":"0","summary":"On December 12, 2025, the investment diary for Hong Kong-listed companies is as follows: **New Listings Activity**   - Wisdom Mining (Under Subscription)   - CIDI (Under Subscription)   - HASHKEY...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"gpt_icon":0},{"id":"1118584289","title":"LEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1118584289","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118584289?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:45","pubTimestamp":1765262705,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$53.6 by the time of writing, with a trading volume of HK$51.26 million. The company announced that during the 67th ASH Annual Meeting held in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","ASH","LU2463526074.USD","BK4109","BK1161","09887","HK0000252152.HKD","HK0000252160.HKD"],"gpt_icon":0},{"id":"1104276130","title":"LEADS BIOLABS-B (09887): LBL-034 Clinical Data Presented at 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1104276130","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104276130?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:32","pubTimestamp":1765103566,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the 67th ASH Annual Meeting was held in Orlando, Florida, from December 6 to 9, 2025. On the first day of the conference, the company's self-developed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4109","HK0000252152.HKD","ASH","09887","HK0000500386.USD","HK0000252160.HKD","LU2463526074.USD"],"gpt_icon":0},{"id":"2589987125","title":"Nanjing Leads Biolabs Unveils Promising Phase I/II Data for LBL-034 in Multiple Myeloma at ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589987125","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589987125?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:14","pubTimestamp":1765102460,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9spvHs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","09887","HK0000252152.HKD"],"gpt_icon":0},{"id":"1175877194","title":"Nanjing Leads Biolabs (09887) Announces November 2025 Share Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=1175877194","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175877194?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:24","pubTimestamp":1764714259,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock code: 09887) released its monthly return for the period ended 30 November 2025, submitted on 03 December 2025. According to the filing, the total authorised and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1191587742","title":"Nanjing Leads Biolabs (9887) Announces NMPA IND Approval for LBL-047 and Global Partnership with Dianthus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587742","media":"Bulletin Express","labels":["corporation","productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587742?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:46","pubTimestamp":1764578773,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that on November 25, 2025, the National Medical Products Administration approved the Investigational New Drug application for its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1105808802","title":"LEADS BIOLABS-B (09887): LBL-047 Receives IND Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1105808802","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105808802?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:36","pubTimestamp":1764578181,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on November 25, 2025, its self-developed investigational drug LBL-047 received Investigational New Drug (IND) approval from China's National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","IND","HK0000252152.HKD","BK1161","09887"],"gpt_icon":0},{"id":"2588006747","title":"Nanjing Leads Biolabs Receives NMPA IND Approval for LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=2588006747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588006747?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:31","pubTimestamp":1764577861,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. announced that its self-developed drug candidate LBL-047 has received Investigational New Drug  approval from the National Medical Products Administration  of China. LBL-047 is notable for being the world's first bispecific fusion protein combining a humanized anti-BDCA2 antibody and an engineered TACI ectodomain to receive IND approval in both China and the United States. The approved clinical trial will be a double-blind, randomized, placebo-controlled study. There are currently no approved clinical trials globally targeting both plasmacytoid dendritic cells  and B cells, positioning LBL-047 as a strong first and best-in-class candidate. The approval is specific to Nanjing Leads Biolabs Co. Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4Rxp3z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09887"],"gpt_icon":0},{"id":"2588747045","title":"Nanjing Leads Biolabs Co Ltd - Lbl-047 Receives Ind Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2588747045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588747045?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:30","pubTimestamp":1764577837,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X40QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD","09887"],"gpt_icon":0},{"id":"1130540191","title":"Nanjing Leads Biolabs Announces H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1130540191","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130540191?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:44","pubTimestamp":1764341044,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (\"Nanjing Leads Biolabs\") has introduced an H Share Award Scheme, formulated in accordance with relevant laws and regulations. The scheme will have a validity period...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1137190048","title":"Nanjing Leads Biolabs (9887) Announces Extraordinary General Meeting on December 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1137190048","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137190048?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:23","pubTimestamp":1764339792,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has released a proxy form for an Extraordinary General Meeting (EGM) scheduled for December 17, 2025, at 10:00 a.m. The EGM will take place on Floor...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1144181751","title":"Nanjing Leads Biolabs (9887) Announces Extraordinary General Meeting on December 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1144181751","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144181751?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:21","pubTimestamp":1764339692,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has announced that an extraordinary general meeting (EGM) will take place on December 17, 2025, at 10:00 a.m. in Nanjing, PRC. The key items on the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1165982662","title":"Nanjing Leads Biolabs (9887) Announces H Share Award Scheme, Proposes Supervisory Committee Cancellation and Articles Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=1165982662","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165982662?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:21","pubTimestamp":1764339684,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has released a circular calling for an Extraordinary General Meeting (EGM) on December 17, 2025. The proposals up for consideration include the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2586738161","title":"Nanjing Leads Biolabs Co. Ltd. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586738161?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:19","pubTimestamp":1764339558,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. will hold an extraordinary general meeting on December 17, 2025, in Nanjing, the People's Republic of China. During the meeting, shareholders will consider and vote on several special resolutions, including the proposed adoption of the H Share Award Scheme and the proposed authorization to the Board and/or the Delegatee to handle matters related to the H Share Award Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDLbfPJxH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"1188323561","title":"Nanjing Leads Biolabs Co., Ltd. (9887) Announces Book Closure for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1188323561","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188323561?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:09","pubTimestamp":1764241786,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (stock code: 9887) has scheduled an extraordinary general meeting (EGM) on Wednesday, December 17, 2025. According to the announcement, the register of members of H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1188166925","title":"Nanjing Leads Biolabs (9887) Announces Proposed H Share Award Scheme and Supervisory Committee Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1188166925","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188166925?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:02","pubTimestamp":1764082960,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that on November 25, 2025, its board of directors approved the proposed adoption of an H Share Award Scheme, alongside the proposed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0481},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.2003},{"period":"6month","weight":0.4143},{"period":"ytd","weight":0.4143}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"LEADS BIOLABS-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LEADS BIOLABS-B,09887,LEADS BIOLABS-B股票,LEADS BIOLABS-B股票老虎,LEADS BIOLABS-B股票老虎国际,LEADS BIOLABS-B行情,LEADS BIOLABS-B股票行情,LEADS BIOLABS-B股价,LEADS BIOLABS-B股市,LEADS BIOLABS-B股票价格,LEADS BIOLABS-B股票交易,LEADS BIOLABS-B股票购买,LEADS BIOLABS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}